Hwang K-T, Kim J, Jung J, Chang JH, Chai YJ, Oh SW et al (2019) Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: a population-based study using SEER database. Clin Cancer Res 25:1970–1979

Article  PubMed  Google Scholar 

Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kümmel S et al (2024) Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med 391:1981–1991

Article  CAS  PubMed  Google Scholar 

Masuda N, Lee S-J, Ohtani S, Im Y-H, Lee E-S, Yokota I et al (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376:2147–2159

Article  CAS  PubMed  Google Scholar 

Wang X, Wang S-S, Huang H, Cai L, Zhao L, Peng R-J et al (2021) Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial. JAMA 325:50–58

Article  CAS  PubMed  Google Scholar 

Haller DG, Cassidy J, Clarke SJ, Cunningham D, Van Cutsem E, Hoff PM et al (2008) Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 26:2118–2123

Article  CAS  PubMed  Google Scholar 

Jones T, Beard V, Mahajan S, Jain AL, Harris LJ, Miller EM et al (2022) A single institution real-world disease free survival analysis of adjuvant capecitabine in TNBC patients with residual disease following neoadjuvant chemotherapy. J Clin Oncol 40:e12502–e12502

Article  Google Scholar 

Lluch A, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J et al (2020) Phase III trial of adjuvant capecitabine after standard neo-/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol 38:203–213

Article  CAS  PubMed  Google Scholar 

Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL et al (2021) Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131. J Clin Oncol 39:2539–2551

Article  CAS  PubMed  PubMed Central  Google Scholar 

AstraZeneca. A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy [Internet]. clinicaltrials.gov; 2024 Jul. Report No.: NCT02032823. Available from: https://clinicaltrials.gov/study/NCT02032823

Bonadio RC, Tarantino P, Testa L, Punie K, Pernas S, Barrios C et al (2022) Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: what are the evidences? Cancer Treat Rev 110:102459

Article  CAS  PubMed  Google Scholar 

Liu M, Qi Y, Wang W, Sun X (2022) Toward a better understanding about real-world evidence. Eur J Hosp Pharm 29:8–11

Article  CAS  PubMed  Google Scholar 

Ruiz-Linares A, Adhikari K, Acuña-Alonzo V, Quinto-Sanchez M, Jaramillo C, Arias W et al (2014) Admixture in Latin America: geographic structure, phenotypic diversity and self-perception of ancestry based on 7,342 individuals. PLoS Genet 10:e1004572

Article  PubMed  PubMed Central  Google Scholar 

von Minckwitz G, Untch M, Blohmer J-U, Costa SD, Eidtmann H, Fasching PA et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796–1804

Article  Google Scholar 

Gown AM (2008) Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 21(Suppl 2):S8-15

Article  CAS  PubMed  Google Scholar 

Tolaney SM, Garrett-Mayer E, White J, Blinder VS, Foster JC, Amiri-Kordestani L et al (2021) Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0. J Clin Oncol 39:2720–2731

Article  PubMed  PubMed Central  Google Scholar 

Park SY, Park B, Yun JK, Kim HR, Kim Y-H, Jeon YJ et al (2025) Proposal of new ypStage grouping system for esophageal squamous cell carcinoma patients who underwent neoadjuvant chemoradiotherapy followed by surgery. Ann Surg 281:288–298

Article  PubMed  Google Scholar 

von den Grün JM, Hartmann A, Fietkau R, Ghadimi M, Liersch T, Hohenberger W et al (2018) Can clinicopathological parameters predict for lymph node metastases in ypT0-2 rectal carcinoma? Results of the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 phase 3 trials. Radiother Oncol 128:557–563

Article  PubMed  Google Scholar 

Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM (2007) Statistics in medicine—reporting of subgroup analyses in clinical trials. N Engl J Med 357:2189–2194

Article  CAS  PubMed  Google Scholar 

Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J et al (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382:810–821

Article  CAS  PubMed  Google Scholar 

Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M et al (2022) Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: neotrip Michelangelo randomized study. Ann Oncol 33:534–543

Article  CAS  PubMed  Google Scholar 

Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer J-U et al (2022) Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol 33:1149–1158

Article  CAS  PubMed  Google Scholar 

Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, Blake-Cerda M, Arce C, Motola-Kuba D et al (2011) Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer 117:3658–3669

Article  PubMed  Google Scholar 

Acevedo F, Walbaum B, Medina L, Merino T, Camus M, Puschel K et al (2023) Clinical characteristics, risk factors, and outcomes in Chilean triple negative breast cancer patients: a real-world study. Breast Cancer Res Treat 197:449–459

Article  PubMed  Google Scholar 

Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ et al (2024) Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 35:159–182

Article  CAS  PubMed  Google Scholar 

National Comprehensive Cancer Network. Breast cancer guidelines [Internet]. NCCN. [cited 2025 May 20]. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419

Pereira MFI, Buzatto IPC, Carrara HHA, de Buono F, O, de Andrade JM, Orlandini LF, et al (2024) Real-world data on adjuvant capecitabine after standard neoadjuvant chemotherapy for triple negative breast cancer. Rev Bras Ginecol Obstet 46:29

Article  Google Scholar 

Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M et al (2022) Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther 22:773–780

Article  PubMed  Google Scholar 

Ma Y, Zhu M, Zhang J, Jiao D, Hou Y, Chen X et al (2025) Efficacy of adjuvant capecitabine in triple-negative breast cancer with residual disease after neoadjuvant therapy: a real-world study. Breast 81:104477

Article  PubMed  PubMed Central  Google Scholar 

Kim MJ, Kim HJ, Kim J-Y, Shin J, Park YH (2025) Effectiveness of adjuvant capecitabine in triple-negative breast cancer patients with residual disease after neoadjuvant treatment: a real-world evidence study in Korea. Clin Breast Cancer. https://doi.org/10.1016/j.clbc.2024.12.019

Article  PubMed  Google Scholar 

Sullivan M, Lei X, Karuturi M, Malinowski C, Giordano SH, Chavez-MacGregor M (2025) Use of adjuvant capecitabine in older patients with early-stage triple-negative breast cancer. Breast Cancer Res Treat 211:213–221

Article  CAS  PubMed  Google Scholar 

White C, Scott RJ, Paul C, Ziolkowski A, Mossman D, Ackland S (2021) Ethnic diversity of DPD activity and the DPYD gene: review of the literature. Pharmgenomics Pers Med 14:1603–1617

CAS  PubMed  PubMed Central  Google Scholar